Physician profile
Jean-Denis Boucher
NPI 1205827532
$20,114.05
in general payments reported to CMS, 2019-2025
34 companies · $2,350 in 2025
The $2,350 reported for 2025 was more than what 80% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,424 · 2020: $685 · 2021: $894 · 2022: $2,118 · 2023: $3,014 · 2024: $2,630 · 2025: $2,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,594 · Education: $399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,594.44 |
| Education | $399.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $5,878.91 | 2019-2024 | Cabtreo, Arazlo |
| Abbvie INC. | $3,453.30 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Regeneron Healthcare Solutions, INC. | $1,553.05 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $1,524.75 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Lilly USA, LLC | $964.39 | 2020-2025 | Ebglyss, Taltz, Olumiant |
| Janssen Biotech, INC. | $951.95 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Genzyme Corporation | $638.59 | 2019-2025 | |
| Paratek Pharmaceuticals, INC. | $626.94 | 2021-2025 | Nuzyra |
| Janssen Scientific Affairs, LLC | $598.71 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $526.08 | 2019 | |
| Incyte Corporation | $479.65 | 2021-2025 | Opzelura |
| Pfizer INC. | $460.72 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $456.09 | 2022-2024 | Sotyktu |
| Ucb, INC. | $417.50 | 2019-2025 | Bimzelx |
| Journey Medical Corporation | $333.49 | 2021-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $178.37 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Dermavant Sciences, INC. | $172.16 | 2022-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.78 | 2022-2024 | Spevigo |
| Novartis Pharmaceuticals Corporation | $159.07 | 2021-2024 | |
| Organon LLC | $149.14 | 2025 | Vtama |
| Organogenesis INC. | $142.47 | 2023-2025 | Puraply, Cygnus Dual, Via Matrix |
| Verrica Pharmaceuticals INC. | $38.05 | 2023-2024 | Ycanth |
| Leo Pharma INC. | $35.37 | 2020-2022 | |
| Amgen INC. | $30.83 | 2021-2022 | |
| Tactile Systems Technology INC | $26.49 | 2020-2022 | |
| Arcutis Biotherapeutics, INC. | $24.69 | 2024 | Zoryve |
| Smith+Nephew, INC. | $23.35 | 2021 | |
| Almirall LLC | $19.25 | 2020 | |
| Stemline Therapeutics INC. | $17.63 | 2021 | |
| Elekta, INC. | $17.12 | 2025 | Flexitron Hdr |
| Sebela Pharmaceuticals INC. | $16.25 | 2019 | |
| Kerecis Limited | $13.49 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Merck Sharp & Dohme LLC | $12.45 | 2019 | |
| Biofrontera INC. | $9.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean-Denis Boucher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.